Fig. 6
From: Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
The structure of CARs and the application of CRISPR/Cas9 in CAR-T cell therapy. a The structure of the first to third generation CARs. b Knock-out of endogenous TCR sites, immune checkpoint protein and major histocompatibility complex class I molecules generates universal CAR-T cells to enhance T cell killing and avoid graft-versus-host disease